Table 5.

Associations between the Four HLA-DRB1 Amino Acids that Differ between Alleles *03:02 and *03:01 and Disease Course and Susceptibility^*

		Amino Acids
		Phenylalanine, Position 26		Glutamate, Position 28		Tyrosine, Position 47		Glycine, Position 86
Cases/Controls	n	OR† (95% CI)	P Value‡	OR† (95% CI)	P Value‡	OR† (95% CI)	P Value‡	OR† (95% CI)	P Value‡
Resolved cases	315	Referent		Referent		Referent		Referent
Persistent	635	1.05 (0.57–1.95)	0.877	0.68 (0.52–0.90)	0.007	0.78 (0.58–1.05)	0.095	0.93 (0.68–1.28)	0.678
Stage IV	193	1.19 (0.52–2.73)	0.673	0.69 (0.47–0.99)	0.046	0.76 (0.51–1.14)	0.184	0.96 (0.63–1.46)	0.851
Unaffecteds	1,467	Referent		Referent		Referent		Referent
All	1,277	1.10 (0.79–1.53)	0.566	1.15 (0.99–1.34)	0.064	0.84 (0.72–0.99)	0.038	1.08 (0.91–1.29)	0.377
Resolved	315	1.08 (0.63–1.84)	0.784	1.61 (1.26–2.07)	1.76 × 10−4	1.09 (0.83–1.42)	0.531	1.14 (0.86–1.51)	0.377
Persistent	635	1.12 (0.73–1.73)	0.591	1.09 (0.90–1.31)	0.383	0.83 (0.68–1.02)	0.077	1.06 (0.85–1.31)	0.624
Stage IV	193	1.27 (0.63–2.56)	0.508	1.10 (0.81–1.49)	0.542	0.83 (0.59–1.15)	0.261	1.09 (0.76–1.54)	0.645

For definition of abbreviations, see Table 4.

^*Results are presented for patients with sarcoidosis with at least 2 years of follow-up. Individuals with disease resolution (“Resolved”) within this time served as controls; individuals with persistent disease (“Persistent”) served as cases. Persistent cases were further broken down to the subset with Scadding stage IV disease (“Stage IV”). Allele association results are also presented for categories of sarcoidosis cases (All, Resolved, Persistent, and Stage IV) compared with unaffected controls.

^†Models were estimated using generalized estimating equations, and the allele ORs are estimated assuming a dominant model, adjusted for sex and genome-wide percent African ancestry.

^‡P values were calculated using a Wald test.